OBJECTIVE: We studied the evolution of drug combinations used, as well as the clinical and immunological profile of patients at initiation of highly active antiretroviral therapy (HAART) between 1996 and 2006 in West Africa. SETTINGS AND METHOD: IeDEA West Africa is a network of HIV care programs established in 2006. We analyzed data from 12 clinical centers treating adults in five countries: Benin, Cote d'Ivoire, Senegal, Gambia, and Mali. Patients 16 years of age or over were included in the study and the following was documented: sex, date of birth and date of initiation of HAART. RESULTS: We included 14,496 adult patients having started HAART, among these 55 % had started HAART between 2005-2006. The proportion of HIV-infected women increased from 46 % in 1996-2000 to 63 % in 2005-2006. The median age at HAART initiation remained constant: 35 years for women and 40 years for men. The proportion of patients having started HAART with a CD4 count<200 cells/microl was 54 % in 1996-2000, and 64 % in 2005-2006. The most frequently prescribed HAART was: AZT/3TC (or d4T/DDI)/IDV (27 %) in 1996-2000; d4T (or AZT)/3TC/EFV (49 %) in 2003-2004, and d4T/3TC/NVP (49 %) in 2005-2006. CONCLUSION: The first line HAART regimen recommended by WHO was initiated in 83 % of cases in 2005-2006. New approaches to an earlier initiation of ART should be explored to reduce mortality in HIV-infected patients on HAART. (c) 2009 Elsevier Masson SAS. All rights reserved.
OBJECTIVE: We studied the evolution of drug combinations used, as well as the clinical and immunological profile of patients at initiation of highly active antiretroviral therapy (HAART) between 1996 and 2006 in West Africa. SETTINGS AND METHOD: IeDEA West Africa is a network of HIV care programs established in 2006. We analyzed data from 12 clinical centers treating adults in five countries: Benin, Cote d'Ivoire, Senegal, Gambia, and Mali. Patients 16 years of age or over were included in the study and the following was documented: sex, date of birth and date of initiation of HAART. RESULTS: We included 14,496 adult patients having started HAART, among these 55 % had started HAART between 2005-2006. The proportion of HIV-infectedwomen increased from 46 % in 1996-2000 to 63 % in 2005-2006. The median age at HAART initiation remained constant: 35 years for women and 40 years for men. The proportion of patients having started HAART with a CD4 count<200 cells/microl was 54 % in 1996-2000, and 64 % in 2005-2006. The most frequently prescribed HAART was: AZT/3TC (or d4T/DDI)/IDV (27 %) in 1996-2000; d4T (or AZT)/3TC/EFV (49 %) in 2003-2004, and d4T/3TC/NVP (49 %) in 2005-2006. CONCLUSION: The first line HAART regimen recommended by WHO was initiated in 83 % of cases in 2005-2006. New approaches to an earlier initiation of ART should be explored to reduce mortality in HIV-infectedpatients on HAART. (c) 2009 Elsevier Masson SAS. All rights reserved.
Authors: Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Jeffrey S A Stringer; Isaac Zulu; Jens Levy; Elizabeth M Stringer; Albert Mwango; Benjamin H Chi; Vilepe Mtonga; Stewart Reid; Ronald A Cantrell; Marc Bulterys; Michael S Saag; Richard G Marlink; Alwyn Mwinga; Tedd V Ellerbrock; Moses Sinkala Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: B Tonwe-Gold; D K Ekouevi; C A Bosse; S Toure; M Koné; R Becquet; V Leroy; P Toro; F Dabis; W M El Sadr; E J Abrams Journal: Trop Med Int Health Date: 2009-02 Impact factor: 2.622
Authors: Olivia Keiser; Kathryn Anastos; Mauro Schechter; Eric Balestre; Landon Myer; Andrew Boulle; David Bangsberg; Hapsatou Touré; Paula Braitstein; Eduardo Sprinz; Denis Nash; Mina Hosseinipour; François Dabis; Margaret May; Martin W G Brinkhof; Matthias Egger Journal: Trop Med Int Health Date: 2008-03-27 Impact factor: 2.622
Authors: Paula Braitstein; Andrew Boulle; Denis Nash; Martin W G Brinkhof; François Dabis; Christian Laurent; Mauro Schechter; Suely H Tuboi; Eduardo Sprinz; Paolo Miotti; Mina Hosseinipour; Margaret May; Matthias Egger; David R Bangsberg; Nicola Low Journal: J Womens Health (Larchmt) Date: 2008 Jan-Feb Impact factor: 2.681
Authors: Paula Braitstein; Martin W G Brinkhof; François Dabis; Mauro Schechter; Andrew Boulle; Paolo Miotti; Robin Wood; Christian Laurent; Eduardo Sprinz; Catherine Seyler; David R Bangsberg; Eric Balestre; Jonathan A C Sterne; Margaret May; Matthias Egger Journal: Lancet Date: 2006-03-11 Impact factor: 79.321
Authors: Antoine Jaquet; Mariam Mama Djima; Patrick Coffie; Henri Die Kacou; Serge P Eholie; Eugene Messou; Albert Minga; Calixte Guehi; Jean Claude Yavo; Emmanuel Bissagnene; Francois Dabis; Didier K Ekouevi Journal: Pharmacoepidemiol Drug Saf Date: 2011-07-07 Impact factor: 2.890
Authors: Olga M Villar-Loubet; Ryan Cook; Nahida Chakhtoura; Karl Peltzer; Stephen M Weiss; Molatelo Elisa Shikwane; Deborah L Jones Journal: AIDS Behav Date: 2013-02
Authors: Baba Maiyaki Musa; Modupe Coker; Scottie Bussell; Muktar Aliyu; Musa Babashani; Hamza Muhammad; Ibrahim Nashabaru; Musa Garbati Journal: Ann Saudi Med Date: 2015 Jul-Aug Impact factor: 1.526